Advertisement
Singapore markets closed
  • Straits Times Index

    3,430.33
    -30.49 (-0.88%)
     
  • S&P 500

    5,427.13
    -128.61 (-2.31%)
     
  • Dow

    39,853.87
    -504.23 (-1.25%)
     
  • Nasdaq

    17,342.41
    -654.99 (-3.64%)
     
  • Bitcoin USD

    64,357.85
    -1,972.69 (-2.97%)
     
  • CMC Crypto 200

    1,311.41
    -26.76 (-2.00%)
     
  • FTSE 100

    8,086.38
    -67.31 (-0.83%)
     
  • Gold

    2,372.70
    -43.00 (-1.78%)
     
  • Crude Oil

    76.66
    -0.93 (-1.20%)
     
  • 10-Yr Bond

    4.2860
    +0.0470 (+1.11%)
     
  • Nikkei

    37,869.51
    -1,285.34 (-3.28%)
     
  • Hang Seng

    17,004.97
    -306.08 (-1.77%)
     
  • FTSE Bursa Malaysia

    1,615.18
    -5.96 (-0.37%)
     
  • Jakarta Composite Index

    7,240.28
    -22.48 (-0.31%)
     
  • PSE Index

    6,670.27
    -82.85 (-1.23%)
     

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

Strong results from Eli Lilly’s obesity medicine in a sleep apnea trial could upset the sleep apnea industry, while greatly expanding insurance coverage for the Lilly drug. Shares of ResMed which sells CPAP machines that treat sleep apnea, were falling sharply Monday. ResMed’s stock was down 11% to $183.34 near midday, putting it on track for its largest decline since Aug. 4, when it dropped 19%, according to Dow Jones Market Data.